HER2 Support Group Forums - View Single Post - Rexin-G(TM), First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic

eric · 11-07-2006, 06:04 AM

http://www.pharma-lexicon.com/medica...p?newsid=56021
Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers.

The milestone article, appearing in this month's issue of the International Journal of Oncology, reports on 3 clinical studies involving patients with various chemo-resistant tumor types who received Rexin-G in Phase I/II and expanded access protocols. In the first study, progressive tumor reduction and/or necrosis were noted in 83% (n = 6) of patients with advanced or metastatic pancreatic cancer, while in the second study, an objective tumor response was observed in 64% (n = 11) of patients with metastatic breast, colon, uterine, muscle and vocal cord cancer, as well as malignant melanoma. Median survival after Rexin-G treatment was 10 months in the first study, and greater than six months in the second study. In the third study, wherein an innovative mathematically calculated optimal dose of Rexin-G (designated "Calculus of Parity") was given to three patients, tumor reduction and/or necrosis were achieved in 100% of patients. Based on these studies, the following conclusions were reached: (i) the functionality of the targeted gene delivery system is profound, (ii) the genetic construct exhibits broad spectrum activity in many resistant tumor types, and (iii) the targeted genetic medicine is exceptionally safe. The lack of systemic toxicity, taken together with the reduction of tumor burden and the enhanced quality-of-life experienced by patients receiving Rexin-G infusions, constitute meaningful clinical benefits that underscore the need for the expedited development of Rexin-G for pancreatic cancer and, potentially, for all solid tumors.

11-07-2006, 06:04 AM	#1
eric Senior Member Join Date: Sep 2005 Posts: 589	Rexin-G(TM), First Tumor-Targeted Gene Therapy Vector, Stymies Metastatic http://www.pharma-lexicon.com/medica...p?newsid=56021 Epeius Biotechnologies today announced the publication of clinical data from studies conducted at the University of the Philippines, Asian Hospital and Medical Center, Makati Medical Center, Manila, Philippines and Lutheran Medical Center, New York, USA, revealing the safety and single agent efficacy of Rexin-G(TM) for the treatment of a broad spectrum of chemotherapy-resistant cancers. The milestone article, appearing in this month's issue of the International Journal of Oncology, reports on 3 clinical studies involving patients with various chemo-resistant tumor types who received Rexin-G in Phase I/II and expanded access protocols. In the first study, progressive tumor reduction and/or necrosis were noted in 83% (n = 6) of patients with advanced or metastatic pancreatic cancer, while in the second study, an objective tumor response was observed in 64% (n = 11) of patients with metastatic breast, colon, uterine, muscle and vocal cord cancer, as well as malignant melanoma. Median survival after Rexin-G treatment was 10 months in the first study, and greater than six months in the second study. In the third study, wherein an innovative mathematically calculated optimal dose of Rexin-G (designated "Calculus of Parity") was given to three patients, tumor reduction and/or necrosis were achieved in 100% of patients. Based on these studies, the following conclusions were reached: (i) the functionality of the targeted gene delivery system is profound, (ii) the genetic construct exhibits broad spectrum activity in many resistant tumor types, and (iii) the targeted genetic medicine is exceptionally safe. The lack of systemic toxicity, taken together with the reduction of tumor burden and the enhanced quality-of-life experienced by patients receiving Rexin-G infusions, constitute meaningful clinical benefits that underscore the need for the expedited development of Rexin-G for pancreatic cancer and, potentially, for all solid tumors.